This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C3720
rdf:type
owl:Class
rdfs:label
Anaplastic Large Cell Lymphoma
owl:equivalentClass
_:vb629593
nci:A10
nci:C3208
nci:A8
nci:C54450
nci:P106
Neoplastic Process
nci:P108
Anaplastic Large Cell Lymphoma
nci:P207
C0206180
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>An aggressive (fast-growing) type of non-Hodgkin lymphoma that is usually of the T-cell type. The cancer cells express a marker called CD30 or Ki-1 on the surface, and may appear in the lymph nodes, skin, bones, soft tissues, lungs, or liver.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P334
9714/3
nci:P363
Malignant
nci:P366
Anaplastic_Large_Cell_Lymphoma
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>anaplastic large cell lymphoma</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000045552</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Anaplastic Large Cell Lymphoma</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source><n0:source-code>TCGA</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ANAPLASTIC LARGE CELL LYMPHOMA</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>3264</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ALCL</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>3264</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Ki-1+ ALCL</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Ki-1+ Anaplastic Large Cell Lymphoma</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ALCL</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000575433</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>ALCL</n0:term-name><n0:term-group>AB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>CD30 Positive Anaplastic Large Cell Lymphoma</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Ki-1 Lymphoma</n0:term-name><n0:term-group>AQS</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Anaplastic Large Cell Lymphoma</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A peripheral (mature) T-cell lymphoma, consisting of usually large anaplastic, CD30 positive cells. The majority of cases are positive for the anaplastic large cell lymphoma (ALK) protein. The most frequently seen genetic alteration is a t(2;5) translocation. Majority of patients present with advanced disease. The most important prognostic indicator is ALK positivity, which has been associated with a favorable prognosis. (WHO, 2001)</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C3720
n5:hasConcept
n6:M0026793
Subject Item
_:vb629593
rdf:type
owl:Class
owl:intersectionOf
_:vb730457
Subject Item
_:vb645781
rdf:type
owl:Restriction
owl:onProperty
nci:R105
owl:someValuesFrom
nci:C37017
Subject Item
_:vb645782
rdf:type
owl:Restriction
owl:onProperty
nci:R108
owl:someValuesFrom
nci:C39715
Subject Item
_:vb645783
rdf:type
owl:Restriction
owl:onProperty
nci:R104
owl:someValuesFrom
nci:C33061
Subject Item
_:vb645784
rdf:type
owl:Restriction
owl:onProperty
nci:R89
owl:someValuesFrom
nci:C36447
Subject Item
_:vb645785
rdf:type
owl:Restriction
owl:onProperty
nci:R89
owl:someValuesFrom
nci:C36448
Subject Item
_:vb730232
rdf:first
nci:C3468
rdf:rest
_:vb748159
Subject Item
_:vb730457
rdf:first
nci:C36025
rdf:rest
_:vb730232
Subject Item
_:vb748159
rdf:first
_:vb645781
rdf:rest
_:vb748160
Subject Item
_:vb748160
rdf:first
_:vb645782
rdf:rest
_:vb748161
Subject Item
_:vb748161
rdf:first
_:vb645783
rdf:rest
_:vb748162
Subject Item
_:vb748162
rdf:first
_:vb645784
rdf:rest
_:vb748163
Subject Item
_:vb748163
rdf:first
_:vb645785
rdf:rest
rdf:nil